NY-MSCI
MSCI Inc. (NYSE: MSCI), a leading provider of investment decision support tools and services, today announced the development of Investment Solutions as a Service for the global investment industry in collaboration with Microsoft Corp. The new service will allow institutional investors to use next generation technologies, advanced analytics and big data to help anticipate and address key strategic and investment challenges.
Built to align long-term technology and data trends with the immediate needs of investors, the service will combine Microsoft’s Cloud and AI technologies with MSCI’s extensive data sets, analytical models and deep expertise of the global investment industry to power next-generation investment decision making.
Investment Solutions as a Service will transform the investment process and experience, beginning with the following services launching in 2021:
- ESG Solutions as a Service
- Index Solutions as a Service
- Data Management Solutions as a Service
- Investment Analytics Solutions as a Service
The launch of these services reflects the increasing demand for technologies that offer “solutions as a service”, harness big data and provide customized experiences. The solutions are a part of the strategic alliance created between MSCI and Microsoft in 2020 to accelerate innovation in the global investment industry.
“The partnership with Microsoft underscores MSCI’s continued commitment to develop new and innovative investing solutions,” said Henry Fernandez, Chairman and CEO, MSCI . “We have combined Microsoft’s best of breed technology with our robust data and analytical capabilities and rigorous understanding of client challenges to create a suite of services to empower investors. From responding to the historic and unrivalled challenge of climate change, to harnessing the power of big data and innovative analytics, Investment Solutions as a Service is a milestone in powering the next generation of investment decision making.”
“MSCI and Microsoft share a commitment to accelerating innovation in the financial services industry,” said Scott Guthrie, Executive Vice President, Cloud + AI, Microsoft. “MSCI’s investment solutions, combined with the data and analytics capabilities of Microsoft Azure, will enable investment managers to harness intelligent insights needed to confidently navigate today’s global markets.”
Environmental, Social and Governance (ESG) Solutions as a Service
With ESG firmly established as a high-priority issue for global investors and corporations, ESG Solutions as a Service will help them better understand, analyze and interpret the investment and business risks and opportunities that climate change brings. Leveraging Microsoft’s Azure and PowerBI platforms, investors will be able to evaluate industries and companies with the world’s leading ESG analytics, and corporations will be able to understand their risk assessment when compared to their peers. The service will provide detailed insights on companies’ adaptive capacity to climate change, carbon footprint measurements, as well as exposure to physical risk, including climate-related events such as hurricanes and flooding.
Index Solutions as a Service
Index Solutions as a Service will provide investors with the opportunity to create and customize indexes, marking the first time clients will have MSCI’s index construction capabilities at their fingertips. The service is aimed at delivering an insightful and efficient experience that shortens the time from market hypothesis to new customized indexes. Built on Microsoft Azure, Index Solutions as a Service leverages the insights created through MSCI’s 50+ years of index experience. It will provide clients with a seamless, self-service experience to create, back test and analyze customized indexes; compare those indexes against established benchmarks; refine their creations through an iterative process and order them from MSCI.
Data Management Solutions as a Service & Investment Analytics Solutions as a Service
With Data Management Solutions as a Service and Investment Analytics Solutions as a Service, investors can directly discover and access in a new and dynamic manner a rich and extensive store of data sets and robust analytical capabilities from MSCI’s powerful investment solutions today. MSCI will be releasing a new Developer Portal offering APIs that seamlessly integrate with clients’ existing ecosystems. Through the Developer Portal, developers and researchers can find, select and analyze historical markets data on a range of asset classes and develop their own investment solutions that meet their specific risk and portfolio construction needs.
“ The launch of MSCI’s Investment Solutions as a Service is the latest example of our continuous innovation and drive to develop cutting-edge technologies,” said Jigar Thakkar, Chief Technology Officer and Head of Engineering, MSCI . “We recognize that our clients are operating in an increasingly complex environment where the need for intelligent insights for portfolio management and risk analysis has never been more important. Our new services will provide a friction-free experience with rapid self-customization and exploration of our data sets, putting power in the hands of investors like never before.”
About MSCI
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com .
The information contained herein (the “Information”) may not be reproduced or redisseminated in whole or in part without prior written permission from MSCI. The Information may not be used to verify or correct other data, to create any derivative works, to create indexes, risk models, or analytics, or in connection with issuing, offering, sponsoring, managing or marketing any securities, portfolios, financial products or other investment vehicles. Historical data and analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information or MSCI index or other product or service constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy. Further, none of the Information or any MSCI index is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. The Information is provided “as is” and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information. NONE OF MSCI INC. OR ANY OF ITS SUBSIDIARIES OR ITS OR THEIR DIRECT OR INDIRECT SUPPLIERS OR ANY THIRD PARTY INVOLVED IN MAKING OR COMPILING THE INFORMATION (EACH, AN “INFORMATION PROVIDER”) MAKES ANY WARRANTIES OR REPRESENTATIONS AND, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH INFORMATION PROVIDER HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WITHOUT LIMITING ANY OF THE FOREGOING AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL ANY OF THE INFORMATION PROVIDERS HAVE ANY LIABILITY REGARDING ANY OF THE INFORMATION FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL (INCLUDING LOST PROFITS) OR ANY OTHER DAMAGES EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited. Privacy notice: For information about how MSCI collects and uses personal data, please refer to our Privacy Notice at https://www.msci.com/privacy-pledge .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005231/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
